Navigation Links
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Date:10/25/2008

ard effective dose regimen of methotrexate alone.

In both studies, nearly one-third of all ACTEMRA (8 mg/kg) patients achieved disease remission (as defined by DAS28 <2.6(2)) and ACTEMRA was generally well-tolerated compared with existing therapies.

About the RADIATE Study

RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs), a three-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the safety and efficacy of ACTEMRA plus methotrexate compared with placebo plus methotrexate in patients who failed to adequately respond to anti-TNF-alpha medications alone.? Between 13-17 percent of the study population experienced three or more prior anti-TNF-alpha failures. Patients were randomized to receive either ACTEMRA intravenously (4 mg/kg or 8 mg/kg) plus methotrexate every four weeks or placebo infusions plus methotrexate weekly for 24 weeks. The study included nearly 500 patients from 128 sites in 13 countries, including the United States. In the study, 50 percent, 29 percent and 12 percent of RA patients treated with ACTEMRA 8 mg/kg plus methotrexate achieved ACR20, ACR50 and ACR70, respectively, and 30 percent, 17 percent and 5 percent of patients in the ACTEMRA 4 mg/kg arm achieved these ACR scores, respectively. In contrast, 10 percent, 4 percent and 1 percent of patients in the control group achieved ACR20, ACR50 and ACR70, respectively. Furthermore, disease remission (DAS28 <2.6) was demonstrated in 30 percent and 8 percent of patients treated with ACTEMRA 8 mg/kg and 4 mg/kg, respectively, compared with 1.6 percent of patients in the control group.

Treatment with ACTEMRA and methotrexate showed significant clinical benefits even in the subgroup analysis of difficult-to-treat patients who received up to three anti-TNF-alpha therapies that failed.

The most common adverse reactions reported most frequently in the ACTEMRA arms of the RADIATE study were diarrhea, upper abdominal pain, rash and dizzine
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
4. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ... reported financial results for the second quarter and three and ... are expressed in Canadian dollars and in accordance with International ... ESSA recorded a net loss of $5.9 million ... 31, 2015 (Q2-2015), compared to a net loss of $0.4 ...
(Date:5/28/2015)... 2015  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... H. Mackaness is scheduled to present at the LD ... PT in Los Angeles . ... on the Event Calendar of the Investors section of IRIDEX,s ... will be available shortly after the conclusion of the presentation ...
(Date:5/28/2015)... 2015 Research and ... of the  "North America Ultrasound Devices Market ... 2019)"  report to their offering.  ... a type of imaging. It uses high-frequency ... and structures inside the body. Health care ...
Breaking Medicine Technology:Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2
... Prolong Pharmaceuticals today announced that industry veteran Glenn Kazo has ... in various capacities with Prolong since 2007. He succeeds Prolong ... "I have known Glenn for more than thirty years," ... Mr. Kazo. "I feel he is one of the greatest ...
... 28 Tigris Pharmaceuticals, Inc., a ... it has completed a private placement of Series ... of approximately $6.5 million.  The financing, which was ... investors Wexford Spectrum Investors, LLC, and Sonostar Capital ...
Cached Medicine Technology:Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President 2Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 2Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 3
(Date:5/29/2015)... 2015 Dr. Rodger Murphree, author ... Syndrome is now offering free weekly call in ... natural ways to reduce symptoms associated with fibromyalgia ... and brain fog. , To find out ... Fibromyalgia call in teleconferences simply go to ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 This ... current state of the Naproxen industry.The report provides ... classifications, applications and industry chain structure. The ... international markets including development trends, competitive landscape analysis, ... are discussed as well as manufacturing processes and ...
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... researchers use percent of body fat data to assess obesity ... obesity rates between African-American //and white women, for example, is ... a much higher risk of obesity than African-American men. ... of body fat is a more accurate measure of fatness ...
... China today agreed to reconduct lab tests to find out ... in Beijing as early as 2003, after eight of its ... ,The Chinese Ministry of Health said it was conducting new ... , ,"In accordance with World Health Organisation and China's ...
... These findings raise the possibility that heart infection could ... that affect humans and livestock //, and that these ... paper is being published on Friday, July 7 in ... ,Prion diseases-also known as transmissible spongiform encephalopathies because ...
... to a study which was published in the International Journal ... against billiary tract cancer //and reduced the risk of developing ... but are fatal. Bile stones on the other hand are ... that about 10% of the patients who had undergone treatment ...
... at Pahihari village near here has caused a scare among ... ,The local Primary Health Centre (PHC) here today constituted a ... to the diseases, they said., ,At least one member ... from either malaria or jaundice, the officials said., ,Bantaram, ...
... to bring ethnic Singapore foods to the U.S., China, ... new frozen food technology.// ,Local food manufacturer, Terry Tan ... ethnic flavors of Singapore available worldwide. ,Extending ... major challenges towards making Terry Tan’s plans a reality. ...
Cached Medicine News:Health News:Prion Disease Agent Causes Heart Damage 2Health News:Prion Disease Agent Causes Heart Damage 3Health News:Prion Disease Agent Causes Heart Damage 4
... a long-pulsed Nd:YAG laser system with a wavelength ... treat deep-lying, superficial as well as red and ... epilation in patients with darker skin types (1 ... as for general improvement of skin texture. The ...
... brachytherapy source consists of a welded titanium ... onto four resin beads. The capsule ... which serve as x-ray markers to identify ... sources are supplied non-sterile when shipped and ...
... SINON is a Q-switched ruby ... of 694 nm. High Performance ... - This combination of high ... in Q-switched mode effectively destroys ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
Medicine Products: